Literature DB >> 16290052

Determination of the cut-off value of serum alanine aminotransferase in patients undergoing hemodialysis, to identify biochemical activity in patients with hepatitis C viremia.

E P A Lopes1, E C Gouveia, A C C Albuquerque, L H B C Sette, L A Mello, R C Moreira, M R C D Coelho.   

Abstract

BACKGROUND: Elevated liver enzymes are infrequent in patients with hepatitis C virus (HCV) infection undergoing chronic hemodialysis (HD), suggesting that the alanine aminotransferase (ALT) is a poor predictor of hepatocellular damage in this population.
OBJECTIVE: To establish a more appropriate cut-off value of ALT to identify biochemical activity due to HCV infection in HD patients. STUDY
DESIGN: A total of 217 patients, with an average age of 51.2 years, were evaluated between January and October 2002; 130 were males (60%). Serum ALT was measured by a kinetic method in five consecutive monthly blood samples, from which an average was obtained and divided by the upper limit of normal (ULN). HCV antibodies were determined using an enzyme immunoassay, the serum HCV-RNA by nested-PCR and HCV genotype by hybridization of the amplified sequence from the 5'-non-coding region. The cut-off value of ALT was obtained from a ROC curve.
RESULTS: Within the 217 patients, 18 (8.3%) were anti-HCV-positive, 17 (7.8%) of whom were also HCV-RNA-positive. Genotype distribution was: 1a=47%; 1b=18%; 3a=35%. Mean ALT/ULN (0.77+/-0.57) of the 18 anti-HCV-positive cases was higher (p<0.001) than the negative group (0.38+/-0.23). The mean ALT/ULN (0.81+/-0.57) of the 17 HCV-RNA-positive cases was also higher (p<0.0001) than the negative cases (0.37+/-0.23). The cut-off value of ALT to distinguish the anti-HCV-positive from negative patients was 0.50% or 50% of the ULN (sensitivity=67%; specificity=83%). According to the HCV-RNA, the cut-off value of ALT was 0.45% or 45% of the ULN (sensitivity=71%; specificity=80%).
CONCLUSION: Reducing the cut-off of ALT by half, enables a better identification of biochemical activity in patients with HCV infection on chronic HD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16290052     DOI: 10.1016/j.jcv.2005.09.010

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  16 in total

1.  Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis.

Authors:  Hidenori Toyoda; Takashi Kumada; Toshifumi Tada; Koichi Takaguchi; Toru Ishikawa; Kunihiko Tsuji; Mikio Zeniya; Etsuko Iio; Yasuhito Tanaka
Journal:  J Gastroenterol       Date:  2016-02-12       Impact factor: 7.527

Review 2.  Hepatitis C in Hemodialysis Units: diagnosis and therapeutic approach.

Authors:  Natasha Silva Constancio; Maria Lucia Gomes Ferraz; Carmen Tzanno Branco Martins; Angiolina Campos Kraychete; Paulo Lisboa Bitencourt; Marcelo Mazza do Nascimento
Journal:  J Bras Nefrol       Date:  2019 Oct-Dec

Review 3.  From bed to bench: which attitude towards the laboratory liver tests should health care practitioners strike?

Authors:  Giovanni Tarantino
Journal:  World J Gastroenterol       Date:  2007-10-07       Impact factor: 5.742

Review 4.  Hepatitis C infection in hemodialysis patients: A review.

Authors:  Digdem Ozer Etik; Serkan Ocal; Ahmet Sedat Boyacioglu
Journal:  World J Hepatol       Date:  2015-04-28

5.  Virological responses of pegylated interferon alpha-2a treatment in hemodialysis patients infected with hepatitis C.

Authors:  Şükran Köse; Süheyla Serin Senger; Gürsel Ersan; Gülsün Çavdar
Journal:  Clin Exp Nephrol       Date:  2012-07-20       Impact factor: 2.801

6.  Determination of the upper cut-off values of serum alanine aminotransferase and aspartate aminotransferase in Chinese.

Authors:  Peng Zhang; Chun-Yan Wang; Yu-Xiang Li; Yu Pan; Jun-Qi Niu; Shu-Mei He
Journal:  World J Gastroenterol       Date:  2015-02-28       Impact factor: 5.742

7.  Occult hepatitis C virus infection among hemodialysis patients.

Authors:  Guillermina Barril; Inmaculada Castillo; María Dolores Arenas; Mario Espinosa; Juan Garcia-Valdecasas; Nuria Garcia-Fernández; Emilio González-Parra; José María Alcazar; Carmen Sánchez; José Carlos Diez-Baylón; Pilar Martinez; Javier Bartolomé; Vicente Carreño
Journal:  J Am Soc Nephrol       Date:  2008-08-06       Impact factor: 10.121

8.  A shield against a monster: Hepatitis C in hemodialysis patients.

Authors:  Seyed-Moayed Alavian
Journal:  World J Gastroenterol       Date:  2009-02-14       Impact factor: 5.742

9.  Clinical significance of alanine aminotransferase levels and the effect of ursodeoxycholic acid in hemodialysis patients with chronic hepatitis C.

Authors:  Chika Nishida; Hirofumi Uto; Makoto Oketani; Koki Tokunaga; Tsuyoshi Nosaki; Mayumi Fukumoto; Manei Oku; Atsushi Sogabe; Akihiro Moriuchi; Akio Ido; Hirohito Tsubouchi
Journal:  J Gastroenterol       Date:  2009-11-05       Impact factor: 7.527

Review 10.  Management of hepatitis C virus infection in hemodialysis patients.

Authors:  Yue-Cheng Yu; Yue Wang; Chang-Lun He; Mao-Rong Wang; Yu-Ming Wang
Journal:  World J Hepatol       Date:  2014-06-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.